Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 726 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenocarcinoma of the Prostate Clear all
Terminated Early Phase 1 Interventional

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

NCT00499733
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Not applicable Interventional

A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients

NCT04946214
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity
Interventions
Smart Water Bottle
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

NCT01848067
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Alisertib, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

NCT03654638
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Dietary Intervention, Questionnaire Administration
Combination Product · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00049257
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00246753
View directory record Official record
Conditions
Prostate Cancer
Interventions
lapatinib ditosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy

NCT00309894
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, ketoconazole, therapeutic hydrocortisone
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 120 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 15, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT05616650
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
18F-DCFPyL, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 2:15 PM EDT
Terminated Phase 1 Interventional

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

NCT05733351
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Fluorescent Imaging of Nerves With Illuminare-1 During Surgery

NCT04983862
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Illuminare-1, Karl Storz D-Light C photodynamic diagnostic (PDD)
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Not applicable Interventional Results available

PET Scan in Treating Patients With Metastatic Prostate Cancer

NCT00002981
View directory record Official record
Conditions
Prostate Cancer
Interventions
positron emission tomography, fludeoxyglucose F 18, methionine C 11
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years to 120 Years · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT01120236
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Bicalutamide, Cixutumumab, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Pharmacological Study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
169
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Rogers, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

NCT02285101
View directory record Official record
Conditions
Melanoma, Prostate Adenocarcinoma
Interventions
PEG-BCT-100
Biological
Lead sponsor
Bio-Cancer Treatment International Limited
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
San Diego, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

NCT00118092
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
tanespimycin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 15, 2026, 2:15 PM EDT
Withdrawn Not applicable Interventional

Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy

NCT02597894
View directory record Official record
Conditions
Stage III Prostate Adenocarcinoma
Interventions
Biopsy of Prostate, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 15, 2026, 2:15 PM EDT
Recruiting Not applicable Interventional

Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer

NCT03880422
View directory record Official record
Conditions
Cancer Survivor, Obesity, Overweight, Prostate Adenocarcinoma, Stage A Prostate Cancer, Stage B Prostate Cancer, Stage C Prostate Cancer, Stage D Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
Interventions
Dietary Intervention, Educational Intervention, Exercise Intervention, Quality-of-Life Assessment, Survey Administration
Dietary Supplement · Other · Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00026377
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, goserelin acetate, leuprolide acetate, SU5416, radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Chicago, Illinois • LaGrange, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 15, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

NCT00780975
View directory record Official record
Conditions
Prostate Cancer
Interventions
Aplidin (plitidepsin)
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

NCT00005028
View directory record Official record
Conditions
Prostate Cancer
Interventions
bryostatin 1, paclitaxel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
4
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2 Interventional

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080678
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

NCT02624518
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

NCT01026623
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Cixutumumab, Diagnostic Laboratory Biomarker Analysis, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 15, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 15, 2026, 2:15 PM EDT